Companies: 10,795·Total market cap: $144.5T
Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc.

MDP.TOTSXHealthcare● Active
$3.95
+$0.04(+1.02%)
Market Cap$127586503
P/E Ratio—
52W High$4.17
52W Low$2.47
Overview

Medexus Pharmaceuticals Inc.（MDP.TO）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

mdp.to · 股价预测 · 1 位分析师（近3月）· FMP · 更新于 2026年3月28日

分析师评级与共识

基于过去 3 个月内 1 位华尔街分析师

SellBuy

Hold

1 位分析师

共识

评级分布

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
合计: 1 · 买入占比: 0.0%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $3.95

Medexus Pharmaceuticals Inc.（MDP.TO）的分析师共识为 Hold，基于过去 3 个月内 1 位华尔街分析师的评级。MDP.TO 的 12 个月平均目标价为 $0.00，相对当前价 $3.95 代表 +0.0% 的潜在上行空间。

短期股价预测

Bull

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-09$3.94↓ 0.31%

1-day model range: $3.92–$3.95. Peak: $3.95 (-0.31%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$5+33.3%
2028$6+55.5%
2029$7+68.5%
2030$7+75.5%
2031—+79.2%
Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BULLISH

Based on 14 technical indicators

93%7%0%
13Buy
1Neutral
0Sell
RSI (14)60.0Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · MDP.TO · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$3.94BUY
MA 10$3.93BUY
MA 20$3.94BUY
MA 50$3.86BUY
MA 100$3.41BUY
MA 200$3.12BUY
Current $MDP.TO · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$3.94BUY
EMA 10$3.94BUY
EMA 20$3.93BUY
EMA 50$3.79BUY
EMA 100$3.54BUY
EMA 200$3.27BUY
Current $MDP.TO · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Canaccord Genuity2022-01-04
Downgrade ↓
Speculative Buy→Hold
Canaccord Genuity2021-08-18
Downgrade ↓
Speculative Buy→Hold
Canaccord Genuity2021-08-17
Downgrade ↓
Speculative Buy→Hold

Wall Street analysts have recently issued updated ratings on Medexus Pharmaceuticals Inc. (MDP.TO) stock. Of the recent 3 rating actions, 0 were upgrades and 3 were downgrades. 1 analysts currently cover MDP.TO.

分析师推荐趋势

Buy ratings0 → 0
Hold ratings2 → 1↓ 1
Sell ratings0 → 0

MDP.TO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$100M

↓ 28.4% YoY

Revenue Next Year

$114M

↑ 14.2% YoY

EPS This Year

$0.00

EPS Next Year

$0.25

↑ 6051.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast MDP.TO EPS of $0.00 for the current fiscal year, based on estimates from 3 analysts. The MDP.TO revenue forecast is $100M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

MDP.TO 股价预测由两类独立数据源支撑：来自 1 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。MDP.TO 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Hold。

MDP.TO 的短期预测（明日）为 $3.94（-0.31%）。 MDP.TO 对 2027 年的股价预测均值为 $5。 MDP.TO 对 2030 年的预测区间为 $7–$7。

Medexus Pharmaceuticals Inc. 在 TSX 上市，代码 MDP.TO。MDP.TO 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 0% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

MDP.TO 预测 · 8 个问题

根据 1 位华尔街分析师，MDP.TO 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $3.95，隐含约 +0.0% 的上行空间。

MDP.TO 目标价MDP.TO 分析师目标价MDP.TO 12个月目标价目标价 MDP.TO

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.